The daily use of specific antiretroviral medications by persons without HIV infection, but at high risk of sexual or injection exposure to HIV, has been shown to be a safe and effective HIV prevention method. The FDA approved the use of Truvada® for preexposure prophylaxis (PrEP) in July 2012 and Public Health Services (PHS) has issued clinical practice guidelines for its use. CDC requests approval to collect data over 3 years that will be used to conduct research with 175 clinicians about their knowledge, attitudes, and practices related to a new intervention (PrEP) over the period of its initial introduction in their clinics. The knowledge gained will be used to refine measurement instruments and methods, develop training and educational resources and tools for use by CDC/Division of HIV/AIDS Prevention-funded partners, and other organizations supporting delivery of PrEP in clinical settings. The results may be shared at scientific meetings, distribution to technical assistance providers for clinical HIV prevention partners, and publication of a report.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.